BioStock Life Science Summit, Lund, October 23 2019, Monica Wallter, CEOPress releases
LIDDS licensee Jiangxi Puheng Pharma prepares for phase III trial in China LIDDS adds Lithuanian clinics to phase I study LIDDS: Liproca® Depot open label extension study indicates PSA reduction for up to one year LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)Events
Presentations
Company Analysis
Photo Library
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2019-11-07 LIDDS licensee Jiangxi Puheng Pharma prepares for phase III trial in China
- 2019-11-06 LIDDS adds Lithuanian clinics to phase I study
- 2019-10-23 LIDDS: Liproca® Depot open label extension study indicates PSA reduction for up to one year
- 2019-09-24 LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
